Loading
Signaling Pathways in Disease / Protease and Inhibitor Mechanisms · Journal article
Asian Journal of Chemistry · September 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage drug discovery study reporting the design, synthesis and in vitro evaluation of a novel phthalimide-anhydride series as MMP-9 suppressors in breast cancer. Compound 5c showed moderate cytotoxicity and concentration-dependent MMP-9 suppression in MCF-7 cells, but acute oral toxicity in rats (LD50 5–50 mg/kg, GHS Category 2) is prohibitive, and the authors explicitly recommend further lead optimization before preclinical development can proceed.
In vitro chemical synthesis, molecular docking, molecular dynamics simulation, and cell-based assays; acute oral toxicity study in rats. MCF-7 breast cancer cell line; rats used for acute toxicity (species and sex mentioned but no counts given).. Intervention: Compound 5c [acetic 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-phenylpropanoic anhydride] and other phthalimide-anhydride derivatives (5a–e) as MMP-9 suppressors.. Compared with: 5-fluorouracil (for cytotoxicity IC50 comparison); vehicle/untreated controls for apoptosis and MMP-9 assays..
Compound 5c achieved highest Glide score of -4.632 kcal/mol in molecular docking and demonstrated 1.5–2.5 Å RMSD stability over 100 ns in molecular dynamics simulations. Compound 5c exhibited IC50 of 27.89 µg/mL (82.7 µM) against MCF-7 breast cancer cells, approaching 5-fluorouracil IC50 of 8.6 µg/mL (66.1 µM). Compound 5c induced early apoptosis in 30.6% of cells versus 9.3% in controls, with little necrosis.
No in vivo efficacy data; single cell line (MCF-7) used for cytotoxicity and MMP-9 studies. Acute toxicity LD50 is a range (5–50 mg/kg) rather than a point estimate; no therapeutic window calculation provided.
This is a bench-stage discovery report with no immediate clinical relevance. The prohibitive acute toxicity profile (GHS Category 2) and lack of in vivo efficacy data mean compound 5c and its series cannot advance to preclinical development without substantial chemical optimization. Clinicians and researchers should await further lead optimization and in vivo studies before considering therapeutic potential.
Early-stage in vitro chemical screening with molecular modelling; no animal efficacy data, significant toxicity concerns (LD50 Category 2), and the authors themselves call for further optimization before preclinical development.
As stated by the source record.
Quoted from the source exactly as published.
This is a bench-stage discovery report with no immediate clinical relevance. The prohibitive acute toxicity profile (GHS Category 2) and lack of in vivo efficacy data mean compound 5c and its series cannot advance to preclinical development without substantial chemical optimization. Clinicians and researchers should await further lead optimization and in vivo studies before considering therapeutic potential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
A novel series of substituted acetic 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)anhydride derivatives (5a-e) was designed and evaluated as potential matrix metalloproteinase-9 (MMP-9) suppressors for breast cancer therapy. Molecular docking using Schrödinger Maestro 2021 (PDB ID: 6ESM) revealed effective chelation of the catalytic Zn2+ ion by all derivatives, with the highest Glide score of -5.900 kcal/mol for compound 5a and a promising -4.632 kcal/mol for lead candidate 5c [acetic 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-phenylpropanoic anhydride]. Molecular dynamics simulations confirmed the compound 5c–MMP-9 complex stability (RMSD: 1.5-2.5 Å over 100 ns). SwissADME predictions indicated drug-like properties, including high gastrointestinal absorption, compliance with Lipinski’s rule of five and no AMES mutagenicity or hERG inhibition. Compounds were synthesised via a two-step protocol involving phthalic anhydride condensation with amino acids followed by acetyl chloride-mediated cyclodehydration, affording yields of 46-65% (compound 5c: 65%). In vitro, compound 5c exhibited moderate cytotoxicity against MCF-7 breast cancer cells (IC50 = 27.89 µg/mL; 82.7 µM), approaching that of 5-fluorouracil (IC50 = 8.6 µg/mL; 66.1 µM) in the same assay system. Flow cytometry showed that compound 5c induced early apoptosis (30.6% vs. 9.3% controls) and little necrosis. ELISA tests indicated that there was a concentration-dependent reduction of MMP-9 in TPA-stimulated MCF-7 cells (64.36% at a concentration of 55.89 µg/mL, 165.7 µM). Acute oral toxicity in rats gave an LD50 cut-off of 5-50 mg/kg (GHS Category 2), limiting the therapeutic window and requiring further optimisation before preclinical development. The phthalimide-anhydride scaffold offers a promising Zn2+-chelating motif with potential selectivity over hydroxamates. Compound 5c merits further lead optimisation, with in vivo efficacy, pharmacokinetics and selectivity against other MMPs requiring evaluation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.